Advisory Research Inc Alnylam Pharmaceuticals, Inc. Transaction History

Advisory Research Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $95,385 - $130,432	-750 Reduced 24.28%	2,339 $382,000
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $33,986 - $44,578	-213 Reduced 6.45%	3,089 $524,000
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $110,337 - $135,024	650 Added 24.51%	3,302 $623,000
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $66,758 - $91,805	519 Added 24.33%	2,652 $450,000
Q1 2021 May 12, 2021	BUY	$126.83 - $175.69 $270,528 - $374,746	2,133 New	2,133 $301,000
Q4 2020 Feb 12, 2021	SELL	$122.97 - $147.0 $389,077 - $465,108	-3,164 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $164,212 - $224,238	1,355 Added 74.9%	3,164 $461,000
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $65,860 - $98,870	-632 Reduced 25.89%	1,809 $268,000
Q1 2020 May 12, 2020	BUY	$93.12 - $133.99 $227,305 - $327,069	2,441 New	2,441 $266,000
Q2 2018 Aug 14, 2018	SELL	$88.31 - $107.8 $258,041 - $314,991	-2,922 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $338,718 - $434,033	2,922 New	2,922 $348,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.